Parallel-group studies have established the efficacy of cholinesterase
inhibitors in Alzheimer's disease, at least for short-term cognitive
and clinical global enhancement. Noncognitive outcomes are currently u
nder scrutiny. Time to reach clinical milestones may be a more useful
trial design for new studies aiming to delay appearance or progression
of disease. Curt Opin Neurol 11:435-438. (C) 1998 Lippincott Williams
& Wilkins.